Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Short Interest in Roche Holding AG (OTCMKTS:RHHBY) Declines By 40.6%
03:48am, Sunday, 01'st Mar 2026
Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 2,782,461 sh
Quantum Strategy's David Roche thinks Iran regime could be 'gone within a year'
12:04am, Friday, 27'th Feb 2026
David Roche of Quantum Strategy explains why he believes Iran's current regime could fall within a year. He also says he does not see Tehran conceding to U.S. demands to limit its nuclear program, vie
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
11:50am, Monday, 23'rd Feb 2026
FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.
FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
02:00am, Friday, 20'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the com
FDA Accepts New Drug Application for Genentech's Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
01:05am, Friday, 20'th Feb 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com
FDA accepts New Drug Application for Roche's giredestrant in ESR1-mutated, ER-positive advanced breast cancer
01:00am, Friday, 20'th Feb 2026
Basel, 20 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has accepted the company's New Drug Application for girede
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
08:30am, Thursday, 19'th Feb 2026
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical com
Change to the Roche Enlarged Corporate Executive Committee
01:00am, Tuesday, 17'th Feb 2026
Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effecti
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MAJESTY study in adults with primary membranous nep
Basel, 16 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistica
3 High-Yield Dividend ETFs Perfect for Those Planning on Retiring
07:30am, Tuesday, 10'th Feb 2026
At 60 and above, many people start thinking differently about investing. At this stage of life, the main goal shifts to steady passive income instead of rapid mega-growth.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
08:14pm, Monday, 09'th Feb 2026
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
03:44pm, Saturday, 07'th Feb 2026
Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple sclerosi
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the
Basel, 07 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK) inhibi
